Paper Details

  1. Home
  2. Paper Details

The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis.

Author: ChenPing, HongJiaze, JinJieyin, NgDerry Minyao, XuYunbao, YangTong, ZhangBeilei, ZhouFeifei, ZhouFengyan, ZhouXinyu

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

FOLFIRINOX treatment showed potential benefits for patients with metastatic pancreatic cancer, improving overall survival (OS) rate (0.76) compared to other chemotherapy regimens. While it had no benefit on progression-free survival, FOLFIRINOX demonstrated superior benefits over monochemotherapy (0.59) and combination chemotherapy (0.76). There was no significant difference between FOLFIRINOX and nab-paclitaxel + gemcitabine (0.91). The main adverse events included hematological toxicity and gastrointestinal issues, such as febrile neutropenia, reduced white blood cell count, decreased appetite, and diarrhea.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The prognosis of pancreatic cancer (PC) is extremely poor, and most patients with metastatic PC still receive palliative care. Here, we report the efficacy and safety of FOLFIRINOX (oxaliplatin, irinotecan, leucovorin, 5-fluorouracil) in the treatment of metastatic PC. METHODS: We searc...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218408/

データ提供：米国国立医学図書館（NLM）

FOLFIRINOX: A Promising Treatment for Metastatic Pancreatic Cancer

The [metastatic pancreatic cancer] landscape is a harsh desert with limited options for treatment. This study dives deep into the potential of [FOLFIRINOX (oxaliplatin, irinotecan, leucovorin, 5-fluorouracil)] as a treatment strategy for this aggressive disease. Researchers conducted a meta-analysis, gathering evidence from various studies to assess the efficacy and safety of FOLFIRINOX. Their findings suggest that this regimen could offer improved overall survival compared to other chemotherapy options, offering a glimmer of hope in this challenging terrain.

FOLFIRINOX: A Fighting Chance Against Pancreatic Cancer

This research, like a camel caravan carrying precious resources across the desert, offers a potential lifeline for those battling pancreatic cancer. The meta-analysis reveals that FOLFIRINOX holds promise in improving overall survival. While the regimen does have potential side effects, the study emphasizes the importance of careful monitoring and personalized management to optimize patient outcomes.

Managing Pancreatic Cancer: A Multifaceted Approach

The fight against pancreatic cancer is a long and arduous journey. This study underscores the need for a multifaceted approach, combining advanced treatments with supportive care and a focus on quality of life. While FOLFIRINOX shows promise, it's essential to consult with healthcare professionals to determine the most appropriate treatment strategy for each individual.

Dr. Camel's Conclusion

This research, like a camel caravan traversing the vast desert of cancer treatment options, offers a hopeful beacon for those facing metastatic pancreatic cancer. While FOLFIRINOX shows promise in improving survival rates, it's important to remember that every patient's journey is unique. By working with healthcare providers and staying informed, we can navigate the challenges of this disease with strength and resilience.

Date :
  1. Date Completed 2021-06-23
  2. Date Revised 2021-06-25
Further Info :

Pubmed ID

34154596

DOI: Digital Object Identifier

PMC8218408

Related Literature

Article Analysis
・Effective treatment of pancreatic cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.